Sat, Jan 31, 2015, 3:18 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

  • jarretthines jarretthines Jul 27, 2012 2:08 PM Flag

    Just noticed this on my brokerage acct ...

    ... its from the day before the new compensation notice and it looks like we arent the only ones unhappy with management.

    UPDATE: Aegis Capital Reiterates Hold Rating, Lowers PT on Protalix BioTherapeutics
    11:34a ET July 16, 2012 (Benzinga)
    In a company update published Monday, Aegis Capital Corporation reiterated its Hold rating on Protalix BioTherapeutics (NYSEAMEX: PLX), but lowered its price target from $7.00 to $5.50.

    Aegis Capital noted, “In our view, Protalix must successfully commercialize its lead drug, Elelyso, to drive significant stock appreciation. Elelyso, a human enzyme produced recombinantly in plant cells, was developed to treat Gaucher's disease, a chronic inheritable enzyme deficiency disorder. In the U.S., Elelyso was approved by the FDA in early May 2012. However, Protalix and its partner Pfizer were recently notified that the European Medicines Agency (EMA) has elected to lock them out of the European market, since Shire holds orphan status in Europe on its Gaucher's disease drug, Vpriv. We think this could delay Elelyso from entering Europe for up to a decade.”

    Protalix BioTherapeutics closed on Friday at $5.80.

2.00-0.02(-0.99%)Jan 30 4:02 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.